BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38760780)

  • 1. The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
    Boutrus RR; Abdelazim YA; Mohammed T; Bayomy M; Ibraheem MH; Hussein A; Sebaie ME
    BMC Cancer; 2024 May; 24(1):599. PubMed ID: 38760780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients.
    Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C
    Breast J; 2014; 20(4):381-7. PubMed ID: 24890310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.
    Beadle BM; Woodward WA; Tucker SL; Outlaw ED; Allen PK; Oh JL; Strom EA; Perkins GH; Tereffe W; Yu TK; Meric-Bernstam F; Litton JK; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):734-44. PubMed ID: 18707822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
    Abdulkarim BS; Cuartero J; Hanson J; Deschênes J; Lesniak D; Sabri S
    J Clin Oncol; 2011 Jul; 29(21):2852-8. PubMed ID: 21670451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
    Wang S; Wen G; Tang Y; Yang Y; Jing H; Wang J; Zhang J; Zhao X; Sun G; Jin J; Song Y; Liu Y; Fang H; Zhang Y; Li Y
    BMC Cancer; 2020 Aug; 20(1):792. PubMed ID: 32838753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer.
    Touboul E; Buffat L; Lefranc JP; Blondon J; Deniaud E; Mammar H; Laugier A; Schlienger M
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1019-28. PubMed ID: 8600084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?
    Fisher BJ; Perera FE; Cooke AL; Opeitum A; Dar AR; Venkatesan VM; Stitt L; Radwan JS
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):551-9. PubMed ID: 9231679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.
    van Tienhoven G; Voogd AC; Peterse JL; Nielsen M; Andersen KW; Mignolet F; Sylvester R; Fentiman IS; van der Schueren E; van Zijl K; Blichert-Toft M; Bartelink H; van Dongen JA
    Eur J Cancer; 1999 Jan; 35(1):32-8. PubMed ID: 10211085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy.
    Keruakous AR; Sadek BT; Shenouda MN; Niemierko A; Abi Raad RF; Specht M; Smith BL; Taghian AG
    Breast Cancer Res Treat; 2014 Jul; 146(2):365-70. PubMed ID: 24952906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate.
    Sweeting RS; Klauber-Demore N; Meyers MO; Deal AM; Burrows EM; Drobish AA; Anders CK; Carey LA
    Am Surg; 2011 Jul; 77(7):850-5. PubMed ID: 21944346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23).
    Park HJ; Shin KH; Kim JH; Ahn SD; Kim JY; Park W; Kim YB; Kim YJ; Kim JH; Kim K; Park KR; Shin HS; Jeong BK; Lee SY; Kim S
    Cancer Res Treat; 2017 Jul; 49(3):739-747. PubMed ID: 27764904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does addition of postmastectomy radiotherapy improve outcome of patients with pT1-2, N0 triple negative breast cancer as compared to breast conservation therapy?
    Raghavan RK; Ibrahim S; Jagathnath Krishna KM; Mathew BS
    J Cancer Res Ther; 2019; 15(5):1031-1034. PubMed ID: 31603106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials.
    Nielsen HM; Overgaard M; Grau C; Jensen AR; Overgaard J
    Radiother Oncol; 2006 May; 79(2):147-55. PubMed ID: 16647152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15-year outcomes in a population-based cohort.
    Cao JQ; Truong PT; Olivotto IA; Olson R; Coulombe G; Keyes M; Weir L; Gelmon K; Bernstein V; Woods R; Speers C; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):509-17. PubMed ID: 25194665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
    Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-stage young breast cancer patients: impact of local treatment on survival.
    Bantema-Joppe EJ; de Munck L; Visser O; Willemse PH; Langendijk JA; Siesling S; Maduro JH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e553-9. PubMed ID: 21601378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.
    Litière S; Werutsky G; Fentiman IS; Rutgers E; Christiaens MR; Van Limbergen E; Baaijens MH; Bogaerts J; Bartelink H
    Lancet Oncol; 2012 Apr; 13(4):412-9. PubMed ID: 22373563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients.
    Vasilyeva E; Hamm J; Nichol A; Isaac KV; Bazzarelli A; Brown C; Lohrisch C; McKevitt E
    Ann Surg Oncol; 2023 Oct; 30(11):6413-6424. PubMed ID: 37358683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.